TEL AVIV, Israel--(BUSINESS WIRE)--Feb. 14, 2006--Compugen Ltd. (Nasdaq:CGEN) announced today the development of an innovative in-silico predictive approach allowing the discovery of novel human transcripts and proteins from portions of so-called “junk DNA”. This methodology has already enabled the discovery by Compugen of several previously unknown therapeutic protein candidates and has been published in Proceedings of the National Academy of Sciences (USA) (Shemesh et al. PNAS, January 31 2006).
